SCHEMBL2848894

SCHEMBL2848894

O=C(O)C(C1CCCC1)C1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 7/20 0.56
ALDH1A1 P00352 3/20 0.40
DPP4 P27487 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.36
CYP3A4 P08684 2/20 0.36
MAPT P10636 2/20 0.36
MEN1 O00255 1/20 0.36
MITF O75030 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
ALOX15 P16050 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
NLRP1 Q9C000 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
KDM4E B2RXH2 1/20 0.36
EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10660120 0.97 EPHX1 (0.61) EPHX1ALDH1A1DPP4SMN1; SMN2CYP3A4
SCHEMBL17316191 0.97 EPHX1 (0.61) EPHX1ALDH1A1DPP4SMN1; SMN2CYP3A4
SCHEMBL66996 0.97 EPHX1 (0.61) EPHX1ALDH1A1DPP4SMN1; SMN2CYP3A4
SCHEMBL849367 0.88 EPHX1 (0.42) EPHX1ALDH1A1MAPTMEN1LMNA
SCHEMBL4454833 0.79 EPHX1 (0.48) EPHX1ALDH1A1DPP4SMN1; SMN2CYP3A4
SCHEMBL30093936 0.77 EPHX1 (0.44) EPHX1ALDH1A1DPP4SMN1; SMN2CYP3A4
SCHEMBL4611368 0.77 EPHX1 (0.44) EPHX1ALDH1A1DPP4SMN1; SMN2CYP3A4
SCHEMBL11197502 0.77 EPHX1 (0.64) EPHX1ALDH1A1DPP4SMN1; SMN2CYP3A4
SCHEMBL2848891 0.77 EPHX1 (0.56) EPHX1ALDH1A1DPP4SMN1; SMN2CYP3A4
SCHEMBL28704681 0.76 EPHX1 (0.39) EPHX1DPP4CPB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217204-B2 Catalyst for asymmetric hydrogenation TAKASAGO INTERNATIONAL CORPORATION (JP) 2012-07-10 US claimed
EP-0209621-B1 AN IMMERSION OIL FOR MICROSCOPE IDEMITSU PETROCHEMICAL CO. LTD. (JP) 1990-05-09 EP claimed
US-4789490-A LIQUID DIENIC POLYMER; CONTROLLED SPECIFIC GRAVITY AND ABBE NUMBER IDEMITSU PETROCHEMICAL CO., LTD. (JP) 1988-12-06 US claimed
EP-0209621-A2 An immersion oil for microscope IDEMITSU PETROCHEMICAL CO. LTD. (JP) 1987-01-28 EP claimed
CN-115385820-A Cationic lipids and uses thereof 英维沃生物科技(苏州)有限公司 2022-11-25 CN disclosed
EP-2438989-B1 USE OF ASYMMETRIC HYDROGENATION CATALYST TAKASAGO PERFUMERY CO LTD (JP) 2016-04-13 EP disclosed
US-9061959-B2 Method for manufacturing optically active menthol TAKASAGO INTERNATIONAL CORPORATION (JP) 2015-06-23 US disclosed
US-9000192-B2 Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same TAKASAGO INTERNATIONAL CORPORATION (JP) 2015-04-07 US disclosed
EP-2646150-A1 CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME Takasago International Corporation (JP) 2013-10-09 EP disclosed
EP-2647616-A1 METHOD FOR MANUFACTURING OPTICALLY ACTIVE MENTHOL Takasago International Corporation (JP) 2013-10-09 EP disclosed
US-20130253228-A1 METHOD FOR MANUFACTURING OPTICALLY ACTIVE MENTHOL TAKASAGO INTERNATIONAL CORPORATION (JP) 2013-09-26 US disclosed
US-20130217895-A1 CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME TAKASAGO INTERNATIONAL CORPORATION (JP) 2013-08-22 US disclosed
WO-2000064940-A1 INSULIN CRYSTALS FOR PULMONARY ADMINISTRATION ELI LILLY AND COMPANY (US) 2000-11-02 WO disclosed
WO-1999032116-A1 INSOLUBLE COMPOSITIONS FOR CONTROLLING BLOOD GLUCOSE ELI LILLY AND COMPANY (US) 1999-07-01 WO disclosed
EP-0925792-A2 Insoluble compositions for controlling blood glucose ELI LILLY AND COMPANY (US) 1999-06-30 EP disclosed
WO-1999021578-A1 INSOLUBLE INSULIN COMPOSITIONS ELI LILLY AND COMPANY (US) 1999-05-06 WO disclosed
EP-0911035-A2 INSOLUBLE INSULIN COMPOSITIONS ELI LILLY AND COMPANY (US) 1999-04-28 EP disclosed
EP-0209621-B1 AN IMMERSION OIL FOR MICROSCOPE IDEMITSU PETROCHEMICAL CO. LTD. (JP) 1990-05-09 EP disclosed
US-4789490-A LIQUID DIENIC POLYMER; CONTROLLED SPECIFIC GRAVITY AND ABBE NUMBER IDEMITSU PETROCHEMICAL CO., LTD. (JP) 1988-12-06 US disclosed
EP-0209621-A2 An immersion oil for microscope IDEMITSU PETROCHEMICAL CO. LTD. (JP) 1987-01-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217895-A1 CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME HMOX1, NQO1, CBR3 EPHX1 931/4885ALDH1A1 61/4885DPP4 4720/4885
US-20130253228-A1 METHOD FOR MANUFACTURING OPTICALLY ACTIVE MENTHOL MSMO1, GGPS1, MAN1B1 EPHX1 40/4885ALDH1A1 79/4885DPP4 3902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.